Efficacy and safety of the weight-loss drug rimonabant - Authors' reply

The Lancet

Volumn 371, Issue 9612, 2008, Pages 556-557

  Astrup, Arne ^a   Christensen, Robin ^b   Bartels, Else Marie ^a   Bliddal, Henning ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIMONABANT;

ANXIETY; BARIATRIC SURGERY; CLINICAL TRIAL; DEPRESSION; DIET THERAPY; EXERCISE; FOLLOW UP; HUMAN; LETTER; OBESITY; PRIORITY JOURNAL; PUBLICATION; RISK FACTOR; SUICIDE;

EID: 38949134781     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60263-9     Document Type: Letter

References (5)

1. Pi-Sunyer F., Aronne L., Heshmati H., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
2. Scheen A., Finer N., Hollander P., Jensen M., and Van Gaal L. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
3. Rucker D., Padwal R., Li S., Curioni C., and Lau D. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335 (2007) 1194-1199
4. Bucher H., Guyatt G., Griffith L., and Walter S. The results of direct and indirect treatment comparisons in meta-analysis of randomized trials. J Clin Epidemiol 50 (1997) 683-691
5. Astrup A. Effect of rimonabant on weight reduction and cardiovascular risk. Lancet 366 (2005) 368